ResMed Inc. ($RMD) Stock Forecast: Down 0.3% Today

What is ResMed Inc.?

ResMed Inc. ($RMD) operates in the sleep tech sector, specializing in sleep apnea devices and cloud-connected sleep data. The company's stock price has been fluctuating recently.

Why is ResMed Inc. going down?

RMD stock is down 0.3% on Jan 13, 2026 18:11

• Bogart Wealth LLC notably increased its stake in ResMed Inc., while company insiders have been selling shares possibly suggesting differing views on the company's potential.
• ResMed's robust Q3 earnings report and revenue growth might have initially boosted investor confidence, but recent insider selling by the CEO and a director could have raised concerns.
• The sale of shares by ResMed director Peter C. Farrell under a pre-arranged trading plan, amid varied analyst ratings, could have intensified the negative sentiment surrounding the stock.
• Despite the positive earnings and institutional investments, the mixture of analyst ratings, insider selling, and market apprehensions about the company's future likely contributed to the bearish movement in ResMed's stock price today.

RMD Price Chart

RMD Technical Analysis

RMD News

Bogart Wealth LLC Boosts Position in ResMed Inc. $RMD

Bogart Wealth LLC significantly increased its stake in ResMed Inc. by 293,433.3% in the third quarter, acquiring 17,606 additional shares to hold a total of 17,612 shares valued at approximately $4.82 million. Despite this institutional buying, company insiders have recently sold 21,594 shares totaling about $5.4 million, though insiders still collectively own roughly 0.65% of ResMed. The medical equipment provider holds a "Moderate Buy" consensus rating from analysts with an average price target of $296.09.

https://www.marketbeat.com/instant-alerts/filing-bogart-wealth-llc-boosts-position-in-resmed-inc-rmd-2026-01-13/

The Truth About ResMed Inc.: Is This Sleep Tech Stock Quietly Going Viral?

ResMed Inc. is a sleep tech giant at the intersection of AI, health data, and aging demographics, specializing in sleep apnea devices and cloud-connected sleep data. Despite recent stock fluctuations, it's presented as a long-term, fundamentals-driven investment rather than a meme stock. The article explores the company's solid business model, its quiet but growing presence in wellness discussions, and its competitive advantage over rivals like Philips, while also addressing potential risks such as regulation and the impact of weight-loss drugs.

https://www.ad-hoc-news.de/boerse/news/ueberblick/the-truth-about-resmed-inc-is-this-sleep-tech-stock-quietly-going-viral/68478578

Oregon Public Employees Retirement Fund Has $4.58 Million Stock Position in ResMed Inc. $RMD

The Oregon Public Employees Retirement Fund significantly increased its stake in ResMed Inc. (NYSE:RMD) by 32.8% in Q3, now owning 16,735 shares valued at $4.58 million. ResMed reported strong Q3 earnings, beating EPS estimates and achieving 9.1% year-over-year revenue growth. Despite recent insider selling by the CEO and a director, institutional investors hold a substantial portion of the company's stock, and analysts maintain a "Moderate Buy" consensus rating with a target price of $296.09.

https://www.marketbeat.com/instant-alerts/filing-oregon-public-employees-retirement-fund-has-458-million-stock-position-in-resmed-inc-rmd-2026-01-11/

Resmed director Farrell sells $497k in shares By Investing.com

ResMed Inc. director Peter C. Farrell sold 2,000 shares of the company's common stock for $497,660 on January 7, 2026. The sale was executed under a pre-arranged trading plan, and Farrell now directly owns 66,773 shares. This transaction comes amidst mixed analyst ratings and recent positive Q4 2025 earnings for ResMed.

https://ng.investing.com/news/insider-trading-news/resmed-director-farrell-sells-497k-in-shares-93CH-2282469

Resmed director Farrell sells $497k in shares

ResMed director Peter C. Farrell sold 2,000 shares of company stock for $497,660 on January 7, 2026, under a pre-arranged trading plan. Following the sale, Farrell directly owns 66,773 shares. This transaction comes amidst mixed analyst ratings for ResMed, with some firms adjusting price targets and ratings based on recent financial performance and market concerns, despite the company exceeding its Q4 2025 revenue forecasts.

https://www.investing.com/news/insider-trading-news/resmed-director-farrell-sells-497k-in-shares-93CH-4439408

Trending Today

Lemonda Inc. ($LMND) Stock Forecast: Up 6.8% Today

Citizens Financial Group Inc. ($CFG) Stock Forecast: Up 6.8% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Up 5.3% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 18.5% Today

Novavax Inc. ($NVAX) Stock Forecast: Up 20.0% Today

Power Integrations Inc. ($POWI) Stock Forecast: Up 5.9% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Up 5.7% Today

Robert Half Inc. ($RHI) Stock Forecast: Up 5.1% Today

Ambarella Inc. ($AMBA) Stock Forecast: Up 5.5% Today

IPG Photonics Corporation ($IPGP) Stock Forecast: Up 6.0% Today

ResMed Inc. Price History

13.00.2026 - RMD Stock was down 0.3%

• Bogart Wealth LLC notably increased its stake in ResMed Inc., while company insiders have been selling shares possibly suggesting differing views on the company's potential.
• ResMed's robust Q3 earnings report and revenue growth might have initially boosted investor confidence, but recent insider selling by the CEO and a director could have raised concerns.
• The sale of shares by ResMed director Peter C. Farrell under a pre-arranged trading plan, amid varied analyst ratings, could have intensified the negative sentiment surrounding the stock.
• Despite the positive earnings and institutional investments, the mixture of analyst ratings, insider selling, and market apprehensions about the company's future likely contributed to the bearish movement in ResMed's stock price today.

25.09.2024 - RMD Stock was up 6.1%

• ResMed's strong Q1 financial results, fueled by growing demand for its sleep devices and masks, have driven a positive trend in its stock.
• The company's solid overall performance, evident in improved margins and surpassing financial projections, has instilled confidence among investors.
• Analysts consider ResMed a resilient player in the medical technology industry, underpinned by strong fundamentals, which likely attracted more investors and contributed to the upward movement in the market.

05.00.2026 - RMD Stock was up 1.3%

• The significant insider selling and institutional ownership of ResMed Inc. could have initially raised concerns among investors, but the company's ability to surpass EPS and revenue expectations likely reassured the market.
• ResMed's strategic shift towards a connected ecosystem for sleep and respiratory care may have sparked investor optimism about the company's long-term growth potential and competitive edge.
• The high institutional ownership, particularly with influential shareholders like The Vanguard Group, Inc., suggests a level of confidence in ResMed's future performance, potentially contributing to the bullish movement in the stock.
• Overall, the combination of positive financial results, strategic positioning in the market, and strong institutional support likely drove the bullish momentum in ResMed's stock today.

05.02.2025 - RMD Stock was down 2.9%

• Today, ResMed's stock experienced a notable bearish trend, potentially due to investors engaging in profit-taking following a substantial 25.6% increase over the past year. Despite the success of the AirSense platform fueling positive momentum, market participants may have chosen to secure their profits, resulting in downward pressure on the stock price.

24.03.2025 - RMD Stock was up 5.1%

• ResMed reported stellar third-quarter fiscal 2025 results, surpassing earnings and revenue estimates, showcasing strong execution across all business areas.
• The appointment of Salli Schwartz as Chief Investor Relations Officer could have instilled confidence in investors, signaling a focus on transparent communication and investor relations.
• The positive market reaction indicates that investors are optimistic about ResMed's future prospects and growth trajectory, driven by robust financial performance and strategic leadership appointments.

31.09.2025 - RMD Stock was down 6.1%

• Despite ResMed (RMD) beating earnings and revenue estimates for Q1, the stock experienced a bearish movement.
• The options market activity suggests that there might be some uncertainty or negative sentiment surrounding the stock.
• Investors may be reacting to factors beyond the quarterly performance, such as future growth projections or market conditions.
• The bearish movement could also be influenced by profit-taking activities following a period of positive performance.

08.03.2025 - RMD Stock was down 5.1%

• ResMed recently introduced NightOwl, an FDA-approved home sleep apnea test in the US. Nevertheless, the stock faced a decline in the market.
• Speculation from sources suggests the stock may not see further growth despite positive earnings estimate revisions.
• Investor expectations for ResMed's performance could have driven a sell-off of the stock following news of the successful product launch.

04.07.2025 - RMD Stock was up 4.0%

• ResMed (RMD) exceeded expectations in Q2 earnings, outperforming projections for both earnings per share and sales.
• Analysts have raised their forecasts for the company following the strong earnings report, signaling confidence in its future performance.
• Surpassing estimates for Q4 earnings and revenue reinforces ResMed's market position and indicates potential for further growth.
• The uptick in ResMed's stock price reflects its robust financial results and positive outlook for the future.

31.00.2025 - RMD Stock was down 5.8%

• ResMed (RMD) reported strong Q2 earnings and revenue surpassing expectations, but the stock faced a bearish trend.
• The stock's decline post-achieving a 52-week high could be attributed to profit-taking, causing a temporary decrease in price.
• Some investors are uncertain about the sustainability of ResMed's growth, leading them to sell shares despite positive financial performance.
• The bearish movement might also stem from broader market shifts or sector rotations, with investors temporarily diverting attention from healthcare stocks.

31.00.2025 - RMD Stock was down 8.3%

• Despite beating Q2 earnings and revenue estimates, the stock experienced a bearish movement.
• Investors might have been expecting even higher earnings and revenue figures, leading to a sell-off after the announcement.
• The market may have reacted negatively to guidance or other forward-looking statements made by the company's management during the earnings call.
• Overall market conditions or external factors could have influenced the bearish sentiment towards ResMed (RMD) despite its positive financial performance.

10.02.2025 - RMD Stock was up 5.2%

• The bullish movement in RMD can be attributed to the strong sales performance of its mask and device products, showcasing the company's ability to meet market demand effectively.
• The success of ResMed's cloud-connected AirSense platform has also played a significant role in driving investor confidence and contributing to the stock's impressive rally.
• Despite concerns about increasing debt levels, the market seems to be focusing more on the company's product innovation and industry outperformance, leading to the bullish movement in the stock.

07.03.2025 - RMD Stock was up 5.7%

• Resmed's stock saw a rise following the successful launch of NightOwl, a home sleep apnea test, in the US.
• The FDA-cleared diagnostic tool is expected to boost the company's market presence and revenue prospects in the sleep apnea sector.
• Investor reactions indicate faith in Resmed's cutting-edge products and its capacity to meet the increasing need for in-home healthcare remedies.